


## PTP1B-IN-3 diammonium

<b>Cat. No.:</b>	HY-15133A
<b>CAS No.:</b>	2702673-78-5
<b>Molecular Formula:</b>	C <sub>12</sub> H <sub>13</sub> BrF <sub>2</sub> N <sub>3</sub> O <sub>3</sub> P
<b>Molecular Weight:</b>	396.12
<b>Target:</b>	Phosphatase
<b>Pathway:</b>	Metabolic Enzyme/Protease
<b>Storage:</b>	-20°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



### BIOLOGICAL ACTIVITY

<b>Description</b>	PTP1B-IN-3 diammonium is a potent and orally active PTP1B inhibitor with IC <sub>50</sub> s of 120 nM for both PTP1B and TCPTP. PTP1B-IN-3 diammonium has antidiabetic and anticancer effects <sup>[1][2]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 120 nM (PTP1B), 120 nM (TCPTP) <sup>[2]</sup>
<b>In Vivo</b>	<p>In diet-induced obese (DIO) mice, PTP1B-IN-3 (compounds 3g) exhibits dose dependent inhibition (60%, 80% and 100% inhibition at 1, 3 and 10 mg/kg, respectively) of glucose excursion when given orally 2 h before oral glucose challenge with an estimated ED<sub>50</sub> of 0.8 mg/kg<sup>[1]</sup>.</p> <p>In the NDL2 Ptpn1 transgenic mice, PTP1B-IN-3 (compounds 3g; orally; 30 mg/kg for 21 days) shows a significant delay in the onset of tumor development in NDL2 Ptpn1<sup>+/+</sup> mice, extending the median tumor free days (T50) from 28 days to 75 days<sup>[1]</sup>.</p> <p>In diet-induced obese (DIO) mice, PTP1B-IN-3 (compounds 3g) exhibits good oral bioavailability (F of 24%), slow clearance (CL of 0.71 mL/kg/min), and good elimination half live (t<sub>1/2</sub> of 6 h). The oral bioavailability in higher species such as rats (F of 4%) and squirrel monkeys (F of 2%) are substantially lower but excellent exposures are achieved with oral dosing<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

### REFERENCES

- [1]. Price N, et al. Safety and Efficacy of a Topical Sodium Channel Inhibitor (TV-45070) in Patients With Postherpetic Neuralgia (PHN): A Randomized, Controlled, Proof-of-Concept, Crossover Study, With a Subgroup Analysis of the Nav1.7 R1150W Genotype. Clin J Pain. 2017 Apr;33(4):310-318.
- [2]. Yongxin Han, et al. Discovery of [(3-bromo-7-cyano-2-naphthyl)(difluoro)methyl]phosphonic acid, a potent and orally active small molecule PTP1B inhibitor. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3200-5.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA